What comes out, must go back in: Court sides with FDA on "same surgical procedure" and "homologous use" definitions governing human cell and tissue products

Hogan Lovells
Contact

FDA authority to crack down on illegally marketed stem cell treatments confirmed -

On 3 June a U.S. District Court in Florida issued a decisive blow against US Stem Cell Clinic LLC, granting the U.S. Food and Drug Administration's (FDA) motion for summary judgment, and stopping the clinic from offering its stem cell therapy to patients. The court found that the population of stromal and vascular cells in the clinic's therapy, known as stromal vascular fraction (SVF), constitutes a biological drug product that FDA must review and license before it can be commercially marketed. The court also found that the clinic's manufacturing procedures and its promotion violated statutory requirements, causing the clinic's cellular product to be adulterated and misbranded. Critically, the court rejected the clinic's argument that because its SVF procedure merely extracts and reinserts cells during the "same surgical procedure," it is exempt from FDA regulation. Instead, the court adopted FDA's view that the clinic's separation of stromal and vascular cells from surgically removed adipose (fat) tissue disqualified the procedure from this exception. The court held that the exception only applies to a procedure where the human cell, tissue, or cellular- or tissue-based product (HCT/P) that is implanted into a patient includes "all" of "the antecedent HCT/P removed from the patient in its original form." The case is a critical ruling supporting FDA's increasing enforcement against stem cell clinics. It also clarifies FDA's authority to regulate SVF therapies in particular, and bolsters FDA's effort to gain more control over the HCT/P field more broadly.

Please see full Publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Hogan Lovells | Attorney Advertising

Written by:

Hogan Lovells
Contact
more
less

Hogan Lovells on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.